Biphenyl-2-ol

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics in vivo

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1997

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: GLP study well documented

Data source

Reference

Reference 1

Reference Type:

study report

Title:

Unnamed

Year:

1997

Report date:

1997

Reference 2

Reference Type:

secondary source

Title:

O-Phenylphenol and its Sodium and Potassium Salts: A Toxicological Assessment

Author:

Bomhard, E. M. et al.

Year:

2002

Bibliographic source:

Crit. Rev. Toxicol. 32(6):551-626

Materials and methods

Objective of study:

metabolism

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

None

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

Biphenyl-2-ol

EC Number:

201-993-5

EC Name:

Biphenyl-2-ol

Cas Number:

90-43-7

Molecular formula:

C12H10O

IUPAC Name:

[1,1'-biphenyl]-2-ol

Radiolabelling:

yes

Test animals

Species:

human

Sex:

male

Administration / exposure

Route of administration:

dermal

Vehicle:

other: 0.4 % solution in iso-propanol

Duration and frequency of treatment / exposure:

8 hour(s)

Doses / concentrations

Remarks:

Doses / Concentrations:
100 µL of 0.4 % (w/v) OPP in isopropanol

No. of animals per sex per dose / concentration:

6 males

Results and discussion

Metabolite characterisation studies

Metabolites identified:

yes

Any other information on results incl. tables

OPP is rapidly absorbed via skin and excreted predominantly via urine.  The vast majority of absorbed material is excreted within the first 24 h  after application. The entire absorbed dose is recovered in excreta, thus  leaving no potential for systemic or dermal accumulation.  
The major metabolite identified in all urine samples analysed was the  sulphate conjugate of OPP. This metabolite accounted for 68.33 % of the  absorbed dose. Conjugation of OPP with glucuronic acid was less  significant, accounting for only 3.46 % of the absorbed dose.  Hydroxylation of the phenol or phenyl ring, followed by conjugation was  shown to be significant, with the glucuronide conjugate of  phenylhydroquinone (PHQ-Gluc) and 2, 4´ dihydroxy biphenyl-sulfate (2,  4´-DHB-Sulf) representing 14.34 % and 12.35 % of the absorbed dose,  respectively. No sulphate conjugates of PHQ was observed in any of the  urine samples analysed, contrary to metabolism of OPP in rat and mouse,  in which comparable amounts of both PHQ-conjugates are found, independent  from the applied dose. 
Low levels of free OPP (0.5 % of absorbed dose) and the glucuronide  conjugate (OPP-Gluc) were observed in the early time intervals. Free OPP  was not observed in any of the analysed samples.

Applicant's summary and conclusion

Conclusions:

Interpretation of results (migrated information): no bioaccumulation potential based on study results